Xiaozhu Liu , Qizhi Yang , Liming Pan , Yanfang Ye , Lirong Kuang , Dandan Xu , Liuhua Wang , Shuang Hu , Yifeng Nie , Jian Huang , Jinxiu Qu , Chenan Liu , Wanyan Tang , Pengpeng Ye , Queran Lin , Ying Hu , Wenyi Jin
{"title":"Burden of respiratory tract cancers in China and its provinces, 1990–2021: a systematic analysis of the Global Burden of Disease Study 2021","authors":"Xiaozhu Liu , Qizhi Yang , Liming Pan , Yanfang Ye , Lirong Kuang , Dandan Xu , Liuhua Wang , Shuang Hu , Yifeng Nie , Jian Huang , Jinxiu Qu , Chenan Liu , Wanyan Tang , Pengpeng Ye , Queran Lin , Ying Hu , Wenyi Jin","doi":"10.1016/j.lanwpc.2025.101485","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Respiratory tract cancers emerged as a public health challenge with the highest incidence and mortality among all cancer types in China, despite many national policies in place, such as early cancer screening. It is of outmost importance to monitor the burden of respiratory tract cancers across China and its provinces for refining health strategies.</div></div><div><h3>Methods</h3><div>Based on Global Burden of Disease (GBD) estimates, the present study investigated the age-sex specific pattern alterations of incidence, prevalence, mortality, and disability adjusted life years (DALYs) of respiratory tract cancers in China from 1990 to 2021, as well as its Estimated Annual Percentage Change (EAPC), Age-Standardized Incidence Rate (ASIR), and Age-Standardized Mortality Rate (ASMR).</div></div><div><h3>Findings</h3><div>Between 1990 and 2021, China experienced an escalation in burdens of respiratory tract cancers, with the new cases surging from 274,752 (95% Uncertainty Interval (UI): 234,741–315,112) to 934,704 (750,040–1,136,938), marking an increase of 240.20% (156.05–342.29). Their attributed deaths similarly increased from 278,235 (238,518–322,013) to 814,121 (652,231–994,858). In 2021, the eastern and northeastern regions reported the highest incidence and mortality rates, particularly Shandong, with the highest new cases at 77,225 (58,842–101,352), while Tibet, Qinghai, and Macau observed the lowest. Regarding laryngeal cancer, Guangdong reported the highest incidence at 3466 (2230–4934), with Hainan exhibiting the highest ASIR at 3.46 (2.10–5.11) per 100,000 person-years and ASMR at 2.11 (1.37–3.09) per 100,000 person-years. Over the same timeframe, the EAPC for the ASIR of tracheal, bronchus, and lung cancer was 0.88 (0.63–1.14), and for ASMR, it was 0.29 (0.05–0.62), signifying an upward trend. Conversely, laryngeal cancer exhibited a stable ASIR with an EAPC of 0.04 (−0.22 to 0.30) and a declining ASMR with an EAPC of −1.69 (−1.80 to 1.59). Tracheal, bronchus, and lung cancer burdens exhibited notable sex differences, with their ASIR being 62.63 (46.50–79.90) per 100,000 person-years in males and 28.16 (22.22–34.90) per 100,000 person-years in females. For laryngeal cancer, the ASIR was 3.12 (2.34–4.04) per 100,000 person-years for males and 0.58 (0.35–0.79) per 100,000 person-years for females. Smoking and air pollution emerged as the predominant risk factors contributed to tracheal, bronchus, and lung cancer, accounting for 61.58% (30.00–82.95) and 25.98% (16.94–35.00) of deaths, respectively. In contrast, smoking contributed more to laryngeal cancer-caused deaths (76.70% [65.55–85.15]), followed by alcohol use (14.52% [7.70–20.99]).</div></div><div><h3>Interpretation</h3><div>The burden of respiratory tract cancers in China has increased over the past three decades, and without intervention, the associated health losses could escalate further. This burden predominantly affected the eastern provinces, particularly impacting older males. Our findings advocate for the formulation of targeted prevention, screening, and intervention strategies based on regional and sex disparities.</div></div><div><h3>Funding</h3><div><span>Bill & Melinda Gates Foundation</span>.</div></div>","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"55 ","pages":"Article 101485"},"PeriodicalIF":7.6000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Lancet Regional Health: Western Pacific","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666606525000227","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Respiratory tract cancers emerged as a public health challenge with the highest incidence and mortality among all cancer types in China, despite many national policies in place, such as early cancer screening. It is of outmost importance to monitor the burden of respiratory tract cancers across China and its provinces for refining health strategies.
Methods
Based on Global Burden of Disease (GBD) estimates, the present study investigated the age-sex specific pattern alterations of incidence, prevalence, mortality, and disability adjusted life years (DALYs) of respiratory tract cancers in China from 1990 to 2021, as well as its Estimated Annual Percentage Change (EAPC), Age-Standardized Incidence Rate (ASIR), and Age-Standardized Mortality Rate (ASMR).
Findings
Between 1990 and 2021, China experienced an escalation in burdens of respiratory tract cancers, with the new cases surging from 274,752 (95% Uncertainty Interval (UI): 234,741–315,112) to 934,704 (750,040–1,136,938), marking an increase of 240.20% (156.05–342.29). Their attributed deaths similarly increased from 278,235 (238,518–322,013) to 814,121 (652,231–994,858). In 2021, the eastern and northeastern regions reported the highest incidence and mortality rates, particularly Shandong, with the highest new cases at 77,225 (58,842–101,352), while Tibet, Qinghai, and Macau observed the lowest. Regarding laryngeal cancer, Guangdong reported the highest incidence at 3466 (2230–4934), with Hainan exhibiting the highest ASIR at 3.46 (2.10–5.11) per 100,000 person-years and ASMR at 2.11 (1.37–3.09) per 100,000 person-years. Over the same timeframe, the EAPC for the ASIR of tracheal, bronchus, and lung cancer was 0.88 (0.63–1.14), and for ASMR, it was 0.29 (0.05–0.62), signifying an upward trend. Conversely, laryngeal cancer exhibited a stable ASIR with an EAPC of 0.04 (−0.22 to 0.30) and a declining ASMR with an EAPC of −1.69 (−1.80 to 1.59). Tracheal, bronchus, and lung cancer burdens exhibited notable sex differences, with their ASIR being 62.63 (46.50–79.90) per 100,000 person-years in males and 28.16 (22.22–34.90) per 100,000 person-years in females. For laryngeal cancer, the ASIR was 3.12 (2.34–4.04) per 100,000 person-years for males and 0.58 (0.35–0.79) per 100,000 person-years for females. Smoking and air pollution emerged as the predominant risk factors contributed to tracheal, bronchus, and lung cancer, accounting for 61.58% (30.00–82.95) and 25.98% (16.94–35.00) of deaths, respectively. In contrast, smoking contributed more to laryngeal cancer-caused deaths (76.70% [65.55–85.15]), followed by alcohol use (14.52% [7.70–20.99]).
Interpretation
The burden of respiratory tract cancers in China has increased over the past three decades, and without intervention, the associated health losses could escalate further. This burden predominantly affected the eastern provinces, particularly impacting older males. Our findings advocate for the formulation of targeted prevention, screening, and intervention strategies based on regional and sex disparities.
期刊介绍:
The Lancet Regional Health – Western Pacific, a gold open access journal, is an integral part of The Lancet's global initiative advocating for healthcare quality and access worldwide. It aims to advance clinical practice and health policy in the Western Pacific region, contributing to enhanced health outcomes. The journal publishes high-quality original research shedding light on clinical practice and health policy in the region. It also includes reviews, commentaries, and opinion pieces covering diverse regional health topics, such as infectious diseases, non-communicable diseases, child and adolescent health, maternal and reproductive health, aging health, mental health, the health workforce and systems, and health policy.